Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrogen Sulfide | 15 | 2023 | 77 | 4.010 |
Why?
|
| Retina | 15 | 2025 | 289 | 2.330 |
Why?
|
| Ciliary Arteries | 5 | 2025 | 10 | 2.180 |
Why?
|
| Ciliary Body | 5 | 2025 | 14 | 1.860 |
Why?
|
| Intraocular Pressure | 3 | 2025 | 132 | 1.520 |
Why?
|
| Cattle | 25 | 2025 | 498 | 1.430 |
Why?
|
| Muscle Relaxation | 3 | 2025 | 19 | 1.390 |
Why?
|
| Iris | 5 | 2010 | 11 | 1.200 |
Why?
|
| D-Aspartic Acid | 6 | 2018 | 8 | 1.100 |
Why?
|
| Ophthalmic Solutions | 4 | 2018 | 18 | 0.960 |
Why?
|
| Kinins | 1 | 2025 | 5 | 0.960 |
Why?
|
| Cysteine | 8 | 2019 | 103 | 0.920 |
Why?
|
| Eye | 4 | 2011 | 77 | 0.870 |
Why?
|
| Muscle Contraction | 4 | 2025 | 67 | 0.800 |
Why?
|
| Isoprostanes | 5 | 2014 | 13 | 0.760 |
Why?
|
| Phenylephrine | 3 | 2025 | 34 | 0.760 |
Why?
|
| Aspartic Acid | 5 | 2018 | 51 | 0.750 |
Why?
|
| Peptides | 1 | 2025 | 372 | 0.740 |
Why?
|
| Animals | 44 | 2025 | 16992 | 0.740 |
Why?
|
| Neurotransmitter Agents | 4 | 2011 | 69 | 0.730 |
Why?
|
| Serotonin Antagonists | 3 | 2018 | 22 | 0.700 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2025 | 1124 | 0.680 |
Why?
|
| Aqueous Humor | 2 | 2017 | 18 | 0.670 |
Why?
|
| Cyclic AMP | 2 | 2012 | 127 | 0.650 |
Why?
|
| Organothiophosphorus Compounds | 4 | 2018 | 8 | 0.600 |
Why?
|
| Morpholines | 4 | 2018 | 72 | 0.580 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2018 | 5 | 0.560 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2018 | 7 | 0.560 |
Why?
|
| Muscle, Smooth | 2 | 2025 | 58 | 0.550 |
Why?
|
| Cystathionine gamma-Lyase | 6 | 2015 | 15 | 0.520 |
Why?
|
| Glaucoma | 2 | 2017 | 100 | 0.520 |
Why?
|
| Sulfides | 7 | 2023 | 78 | 0.510 |
Why?
|
| Piperidines | 3 | 2015 | 83 | 0.500 |
Why?
|
| Eye Diseases | 3 | 2018 | 29 | 0.490 |
Why?
|
| Norepinephrine | 5 | 2015 | 97 | 0.460 |
Why?
|
| Sympathetic Nervous System | 3 | 2015 | 57 | 0.460 |
Why?
|
| Pyrrolidines | 1 | 2015 | 31 | 0.450 |
Why?
|
| Cystathionine beta-Synthase | 5 | 2015 | 16 | 0.450 |
Why?
|
| Organophosphorus Compounds | 1 | 2015 | 37 | 0.450 |
Why?
|
| Glycine | 4 | 2012 | 47 | 0.450 |
Why?
|
| Citrates | 5 | 2009 | 18 | 0.440 |
Why?
|
| Tritium | 6 | 2011 | 46 | 0.430 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 140 | 0.420 |
Why?
|
| Vasodilation | 1 | 2013 | 64 | 0.400 |
Why?
|
| Carbachol | 3 | 2025 | 18 | 0.390 |
Why?
|
| Potassium Chloride | 3 | 2009 | 24 | 0.380 |
Why?
|
| Swine | 6 | 2023 | 212 | 0.370 |
Why?
|
| KATP Channels | 4 | 2015 | 10 | 0.360 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2012 | 31 | 0.360 |
Why?
|
| Hydrogen Peroxide | 4 | 2021 | 190 | 0.330 |
Why?
|
| Catecholamines | 2 | 2018 | 45 | 0.320 |
Why?
|
| Cataract | 2 | 2021 | 47 | 0.310 |
Why?
|
| Oxidative Stress | 6 | 2021 | 1003 | 0.300 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 11 | 0.290 |
Why?
|
| Air Pollutants | 1 | 2009 | 130 | 0.280 |
Why?
|
| Peroxides | 2 | 2005 | 19 | 0.270 |
Why?
|
| Lutein | 2 | 2024 | 6 | 0.270 |
Why?
|
| Histamine | 1 | 2006 | 19 | 0.250 |
Why?
|
| Ischemia | 1 | 2006 | 47 | 0.240 |
Why?
|
| Regional Blood Flow | 1 | 2025 | 53 | 0.240 |
Why?
|
| Receptors, Bradykinin | 1 | 2025 | 2 | 0.240 |
Why?
|
| Vasoconstriction | 1 | 2025 | 42 | 0.230 |
Why?
|
| Free Radicals | 1 | 2005 | 70 | 0.230 |
Why?
|
| Cannabinoids | 1 | 2006 | 73 | 0.230 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 35 | 0.220 |
Why?
|
| Vasoconstrictor Agents | 2 | 2015 | 39 | 0.220 |
Why?
|
| Arachidonic Acids | 1 | 2004 | 25 | 0.210 |
Why?
|
| Carotenoids | 1 | 2024 | 74 | 0.210 |
Why?
|
| Alanine | 1 | 2003 | 34 | 0.210 |
Why?
|
| Prostaglandins | 3 | 2015 | 23 | 0.200 |
Why?
|
| Isometric Contraction | 2 | 2015 | 25 | 0.190 |
Why?
|
| Appetite Depressants | 1 | 2002 | 5 | 0.190 |
Why?
|
| Body Weight | 4 | 2007 | 429 | 0.190 |
Why?
|
| Neurons | 1 | 2009 | 1263 | 0.180 |
Why?
|
| Glucose | 1 | 2003 | 244 | 0.180 |
Why?
|
| Alkynes | 2 | 2012 | 52 | 0.170 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2012 | 28 | 0.160 |
Why?
|
| Plant Extracts | 2 | 2004 | 302 | 0.160 |
Why?
|
| Prostaglandins F, Synthetic | 2 | 2016 | 6 | 0.150 |
Why?
|
| Receptors, Muscarinic | 2 | 2010 | 16 | 0.150 |
Why?
|
| Thioctic Acid | 2 | 2016 | 16 | 0.150 |
Why?
|
| Nitric Oxide | 2 | 2015 | 386 | 0.150 |
Why?
|
| Antioxidants | 4 | 2024 | 443 | 0.150 |
Why?
|
| Lens, Crystalline | 1 | 2019 | 39 | 0.150 |
Why?
|
| Chromaffin Cells | 1 | 2018 | 4 | 0.140 |
Why?
|
| Ophthalmic Artery | 1 | 2018 | 4 | 0.140 |
Why?
|
| Excitatory Amino Acids | 1 | 2017 | 7 | 0.140 |
Why?
|
| Exocytosis | 1 | 2018 | 49 | 0.140 |
Why?
|
| Dinoprostone | 2 | 2009 | 64 | 0.130 |
Why?
|
| Anterior Eye Segment | 1 | 2017 | 9 | 0.130 |
Why?
|
| Receptors, Thromboxane | 2 | 2008 | 2 | 0.130 |
Why?
|
| Dinoprost | 2 | 2008 | 19 | 0.130 |
Why?
|
| Organ Culture Techniques | 2 | 2008 | 101 | 0.120 |
Why?
|
| Uvea | 1 | 2015 | 3 | 0.120 |
Why?
|
| Glutamic Acid | 2 | 2009 | 131 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2024 | 213 | 0.120 |
Why?
|
| Software Design | 1 | 2015 | 18 | 0.110 |
Why?
|
| Calcium | 1 | 2018 | 491 | 0.110 |
Why?
|
| Liver | 3 | 2009 | 511 | 0.110 |
Why?
|
| Rats | 6 | 2012 | 3735 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 269 | 0.110 |
Why?
|
| Electric Stimulation | 3 | 2015 | 186 | 0.110 |
Why?
|
| DNA Fragmentation | 2 | 2004 | 98 | 0.100 |
Why?
|
| Lipid Peroxidation | 2 | 2004 | 140 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 74 | 0.100 |
Why?
|
| Humans | 12 | 2024 | 43102 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 458 | 0.100 |
Why?
|
| Synaptic Transmission | 2 | 2015 | 149 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1621 | 0.090 |
Why?
|
| Aminooxyacetic Acid | 1 | 2012 | 3 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 18 | 0.090 |
Why?
|
| Serotonin | 2 | 2002 | 123 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2023 | 465 | 0.090 |
Why?
|
| Glutathione | 3 | 2021 | 171 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 462 | 0.080 |
Why?
|
| Cholinergic Agonists | 1 | 2010 | 6 | 0.080 |
Why?
|
| Glyburide | 1 | 2010 | 9 | 0.080 |
Why?
|
| Receptors, Serotonin | 2 | 2018 | 23 | 0.080 |
Why?
|
| Receptors, Prostaglandin | 1 | 2009 | 7 | 0.080 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2009 | 5 | 0.080 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2009 | 14 | 0.080 |
Why?
|
| Superoxide Dismutase | 2 | 2021 | 158 | 0.080 |
Why?
|
| Glutamine | 1 | 2009 | 36 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 33 | 0.080 |
Why?
|
| Hydrogen | 2 | 2021 | 47 | 0.080 |
Why?
|
| Anti-Obesity Agents | 1 | 2009 | 11 | 0.080 |
Why?
|
| Drug Delivery Systems | 2 | 2024 | 277 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2008 | 2 | 0.070 |
Why?
|
| Flurbiprofen | 2 | 2009 | 5 | 0.070 |
Why?
|
| Miotics | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hydrazines | 2 | 2009 | 22 | 0.070 |
Why?
|
| Sus scrofa | 1 | 2008 | 19 | 0.070 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2009 | 34 | 0.070 |
Why?
|
| Weight Loss | 1 | 2009 | 137 | 0.070 |
Why?
|
| Biguanides | 2 | 2003 | 7 | 0.060 |
Why?
|
| Histamine Agonists | 1 | 2006 | 1 | 0.060 |
Why?
|
| Receptors, Histamine | 1 | 2006 | 3 | 0.060 |
Why?
|
| Histamine Antagonists | 1 | 2006 | 6 | 0.060 |
Why?
|
| Garcinia cambogia | 2 | 2004 | 2 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2004 | 1766 | 0.060 |
Why?
|
| Bradykinin | 1 | 2025 | 25 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2004 | 260 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2007 | 201 | 0.060 |
Why?
|
| Solubility | 1 | 2024 | 139 | 0.050 |
Why?
|
| Nitrendipine | 1 | 2003 | 1 | 0.050 |
Why?
|
| Diltiazem | 1 | 2003 | 4 | 0.050 |
Why?
|
| Biological Availability | 1 | 2024 | 116 | 0.050 |
Why?
|
| Verapamil | 1 | 2003 | 7 | 0.050 |
Why?
|
| Drug Stability | 1 | 2024 | 129 | 0.050 |
Why?
|
| omega-Conotoxins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Perfusion | 1 | 2003 | 38 | 0.050 |
Why?
|
| Kainic Acid | 1 | 2003 | 48 | 0.050 |
Why?
|
| Receptors, Glutamate | 1 | 2003 | 28 | 0.050 |
Why?
|
| Dizocilpine Maleate | 1 | 2003 | 43 | 0.050 |
Why?
|
| Macular Degeneration | 1 | 2024 | 31 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 55 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2003 | 59 | 0.050 |
Why?
|
| Polyamines | 1 | 2003 | 32 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 195 | 0.050 |
Why?
|
| Tryptamines | 1 | 2002 | 7 | 0.050 |
Why?
|
| Dermis | 1 | 2002 | 9 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2002 | 38 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 458 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 182 | 0.050 |
Why?
|
| Appetite | 1 | 2002 | 21 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 48 | 0.050 |
Why?
|
| Testis | 1 | 2003 | 207 | 0.050 |
Why?
|
| Vitamin E | 1 | 2002 | 62 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 57 | 0.050 |
Why?
|
| Inflammation | 1 | 2007 | 758 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 241 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1596 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 306 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 55 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1151 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2002 | 469 | 0.040 |
Why?
|
| Cytosol | 1 | 2018 | 97 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 87 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2018 | 73 | 0.030 |
Why?
|
| Retinal Diseases | 1 | 2017 | 20 | 0.030 |
Why?
|
| Potassium | 1 | 2018 | 109 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 108 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2018 | 107 | 0.030 |
Why?
|
| Male | 5 | 2016 | 23409 | 0.030 |
Why?
|
| Sulfonamides | 2 | 2009 | 91 | 0.030 |
Why?
|
| Rabbits | 1 | 2016 | 278 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 666 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 523 | 0.030 |
Why?
|
| Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide | 1 | 2009 | 1 | 0.020 |
Why?
|
| Xanthones | 1 | 2009 | 5 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 6 | 0.020 |
Why?
|
| Benzofurans | 1 | 2009 | 22 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 53 | 0.020 |
Why?
|
| Time Factors | 2 | 2004 | 1857 | 0.020 |
Why?
|
| Female | 3 | 2004 | 24698 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2007 | 24 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 127 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 147 | 0.020 |
Why?
|
| Eating | 1 | 2007 | 167 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2004 | 7 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 667 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2004 | 31 | 0.010 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2003 | 2 | 0.010 |
Why?
|
| Organ Size | 1 | 2004 | 170 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2004 | 77 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2004 | 63 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 112 | 0.010 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2002 | 7 | 0.010 |
Why?
|
| Tropanes | 1 | 2002 | 7 | 0.010 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Leptin | 1 | 2003 | 118 | 0.010 |
Why?
|
| Inhalation Exposure | 1 | 2002 | 44 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 123 | 0.010 |
Why?
|
| Prodrugs | 1 | 2002 | 31 | 0.010 |
Why?
|
| Tocopherols | 1 | 2002 | 65 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 241 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 256 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2004 | 172 | 0.010 |
Why?
|
| Melatonin | 1 | 2002 | 82 | 0.010 |
Why?
|
| Curcumin | 1 | 2002 | 118 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 532 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 1869 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 6644 | 0.010 |
Why?
|